DE602006020864D1 - 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten - Google Patents

2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten

Info

Publication number
DE602006020864D1
DE602006020864D1 DE602006020864T DE602006020864T DE602006020864D1 DE 602006020864 D1 DE602006020864 D1 DE 602006020864D1 DE 602006020864 T DE602006020864 T DE 602006020864T DE 602006020864 T DE602006020864 T DE 602006020864T DE 602006020864 D1 DE602006020864 D1 DE 602006020864D1
Authority
DE
Germany
Prior art keywords
sup
adenosine receptor
pyrimidines
amido
hetero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020864T
Other languages
English (en)
Inventor
Deborah Slee
Marion Lanier
Binh G Vong
Yongsheng Chen
Xiaohu Zhang
Emily Lin
Manisha Moorjani
Palomino Laria Julio Cesar Castro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall SA filed Critical Almirall SA
Publication of DE602006020864D1 publication Critical patent/DE602006020864D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602006020864T 2005-04-11 2006-04-11 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten Active DE602006020864D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67048205P 2005-04-11 2005-04-11
PCT/US2006/013940 WO2006110884A2 (en) 2005-04-11 2006-04-11 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
DE602006020864D1 true DE602006020864D1 (de) 2011-05-05

Family

ID=36686015

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020864T Active DE602006020864D1 (de) 2005-04-11 2006-04-11 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten

Country Status (5)

Country Link
US (1) US20080275064A1 (de)
EP (1) EP1888565B1 (de)
AT (1) ATE502936T1 (de)
DE (1) DE602006020864D1 (de)
WO (1) WO2006110884A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976851A2 (de) * 2006-01-17 2008-10-08 Neurocrine Biosciences, Inc. Phenoxy-substitutierte pyrimidine als adenosinrezeptor-antagonisten
WO2008070661A1 (en) * 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
US20100249084A1 (en) * 2007-03-21 2010-09-30 Youngsheng Chen Substituted pyrimidines as adenosine receptor antagonists
JP5498396B2 (ja) * 2007-12-21 2014-05-21 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
CN103626741A (zh) * 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
CN103664908A (zh) * 2013-12-10 2014-03-26 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
BR112018002585A2 (pt) 2015-08-11 2018-10-16 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amina para uso no tratamento de câncer
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN114469957B (zh) * 2022-04-15 2022-06-24 山东第一医科大学第一附属医院(山东省千佛山医院) 化合物在制备α-葡萄糖苷酶抑制剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6518424B1 (en) * 1998-11-12 2003-02-11 Elan Pharmaceuticals, Inc. Substituted pyrimidine compositions and methods of use
HUP0300029A2 (en) * 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use
US7189717B2 (en) * 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
TWI330183B (de) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
GB0323138D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
GB0323137D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
US20080058356A1 (en) * 2003-12-15 2008-03-06 Neurocrine Biosciences, Inc. 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists

Also Published As

Publication number Publication date
WO2006110884A8 (en) 2006-12-14
EP1888565B1 (de) 2011-03-23
WO2006110884A2 (en) 2006-10-19
ATE502936T1 (de) 2011-04-15
US20080275064A1 (en) 2008-11-06
WO2006110884A3 (en) 2006-11-23
EP1888565A2 (de) 2008-02-20

Similar Documents

Publication Publication Date Title
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
MY143834A (en) Thrombin receptor antagonists
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
DE602007005241D1 (de) Purin-derivate als a2a-rezeptor-agonisten
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
MY130803A (en) New quinuclidine amide derivatives
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
ATE396183T1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists